Ace Blend raises $9.9 million for trials, new products
Ace Blend said its $9.9 million Series A2 raise would support clinical trials, supply-chain improvements, research and development, and new nutrition formats. It also planned automated batch testing and new products.
Ace Blend raised $9.9 million in a Series A2 round led by 3one4 Capital, with participation from existing investor Fireside Ventures. The company said it would use the proceeds for clinical trials, supply-chain improvements, research and development, and new nutrition formats.1
Founder Shivam Hingorani told Inc42 that contract research organizations would conduct the trials, which were intended for publication in peer-reviewed international journals. He said Ace Blend also planned automated batch-by-batch testing for nutritional accuracy, pesticide residues and heavy metals, as well as shelf-stability studies at launch and six months later.1
Ace Blend’s portfolio included about 14 products, such as plant-based protein powders, superfood mixes and supplements for recovery and strength. Hingorani said the company was developing a gut-health formula, a natural-nutrient product intended to lower inflammation, an eye-health product and a fibre-based gut-health format.1
